Methanex Corp. Form 6-K Summary
Business Context and Reporting Period
Company: Methanex Corporation
Filing Date: August 26, 2024
Document Type: Form 6-K (Report of Foreign Private Issuer)
Subject: Execution of an Amended and Restated Credit Agreement (2024) dated for reference April 24, 2024.
Counterparties: Methanex Corporation (Borrower), Royal Bank of Canada (Agent Bank), and a syndicate of lenders including BNP Paribas, HSBC Bank USA, JPMorgan Chase Bank, Bank of America, The Bank of Nova Scotia, Export Development Canada, and ATB Financial.
Key Financial Metrics and Facility Terms
The filing details the terms of a new revolving credit facility rather than reporting operational financial results (revenue, profit, cash flow) for a specific period. Key facility metrics include:
- Total Commitment: US$500 million aggregate.
- Tranche A: US$300 million revolving facility maturing April 24, 2028.
- Tranche B: US$200 million revolving facility maturing April 24, 2026.
- Purpose: General corporate purposes, working capital, and capital expenditures.
- Currencies: US Dollars and Canadian Dollars.
- Interest Benchmarks: SOFR (US Base Rate), CORRA (Cdn Prime Rate), and Term SOFR/Term CORRA.
- Security: The facility is secured by the "Medicine Hat Security" (mortgage and security interest over the Medicine Hat Plant assets), subject to a limit of 10% of Consolidated Net Worth.
Material Changes and Covenants
The agreement replaces the 2023 Amended and Restated Credit Agreement. Key covenant thresholds and structural changes include:
- Funded Debt Ratio: Borrower must not permit the ratio to exceed 60.0% (subject to reduction to 55% if an ICR Waiver Period is elected).
- Interest Coverage Ratio (ICR): Borrower must not permit the ratio to be less than 2.0:1 (subject to reduction to 1.0:1 during an ICR Waiver Period).
- ICR Waiver Period: The Borrower has the option to elect a waiver period once, which permanently reduces the Funded Debt Ratio limit to 55% and temporarily reduces the ICR to 1.0:1. This election requires specific conditions, including the delivery of the Medicine Hat Security to escrow.
- Accordion Feature: Borrower may request an increase in commitments up to US$100 million (totaling US$600 million) subject to lender participation.
- Restricted Payments: During an ICR Waiver Period, restricted payments are permitted only if unadvanced commitments are at least US$100 million.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no management commentary, earnings guidance, or outlook regarding future revenue or profitability. It is strictly a disclosure of debt financing terms.
Risks and Contingencies:
- Events of Default: Include failure to pay principal/interest, breach of covenants, cross-defaults on debt exceeding US$50 million, bankruptcy, and Material Adverse Effect (excluding changes in methanol prices).
- Security Release: The Medicine Hat Security may be released if the Borrower maintains minimum credit ratings (BBB-/Ba1 or BB+/Baa3) and complies with financial covenants.
- Sanctions and Compliance: Borrower represents compliance with Anti-Corruption Laws and Sanctions (e.g., no dealings with Iran, Syria, North Korea, Cuba, Crimea).
- Environmental Liability: Borrower indemnifies lenders against liabilities arising from breaches of Environmental Laws.
Investor Verification Checklist
- Verify the current credit ratings of Methanex Corporation to determine the applicable interest rate margin (Schedule 12).
- Confirm the current status of the "Medicine Hat Security" and whether it is held in escrow or released.
- Review the most recent quarterly financial statements to calculate the current Funded Debt Ratio and Interest Coverage Ratio against the 60.0% and 2.0:1 thresholds.
- Check for any existing defaults or events of default under other material debt agreements (threshold US$50 million).
- Assess the impact of the "ICR Waiver Period" option on future financial flexibility and covenant headroom.